ABSTRACT Differential renal expression of a homolog of the angiotensin-converting enzyme (ACE), that is, ACE2, has been implicated as a genetic basis of polygenetic hypertension in the

stroke-prone spontaneously hypertensive rat model. However, data on the role of ACE2 in hypertension are still inconclusive. Therefore, we analyzed kidney ACE2 mRNA, ACE2 protein and ACE2

enzyme activities in the adult polygenetic stroke-prone spontaneously hypertensive rat (SHRSP) and the monogenetic TGR(mREN2)27 rat models, in comparison with their normotensive reference

strains, Wistar-Kyoto (WKY) and Spraque-Dawley (SD) rats, respectively. Kidney ACE2 mRNA was studied using quantitative real-time reverse transcriptase-PCR (RT-PCR) in cortex and medulla,

activities were not different from their respective WKY and SD reference strain, respectively. In addition, when we looked at renal localization, we found ACE2 protein to be predominantly

present in glomeruli and endothelium with weak staining in distal and negative staining in proximal tubuli. Thus, our data challenge previous work that implicates ACE2 as a candidate gene

for hypertension in SHRSP by reporting a significant reduction of ACE2 in the kidneys of SHRSP. Taken together, renal ACE2 is not altered in the SHRSP and TGR(mREN2)27 genetic rat models

with established hypertension. SIMILAR CONTENT BEING VIEWED BY OTHERS _CPXM2_ AS A NOVEL CANDIDATE FOR CARDIAC HYPERTROPHY AND FAILURE IN HYPERTENSION Article Open access 16 December 2021

P2X7 RECEPTOR KNOCKOUT DOES NOT ALTER RENAL FUNCTION OR PREVENT ANGIOTENSIN II-INDUCED KIDNEY INJURY IN F344 RATS Article Open access 26 April 2024 BLOCKAGE OF UCHL1 ACTIVITY ATTENUATES

CARDIAC REMODELING IN SPONTANEOUSLY HYPERTENSIVE RATS Article 15 June 2020 INTRODUCTION Angiotensin-converting enzyme (ACE), a key enzyme of the renin–angiotensin system (RAAS), has a

crucial role in renal (patho) physiology. It converts Angiotensin (Ang) I into AngII, a potent vasoconstrictive, pro-inflammatory and pro-fibrotic peptide. The only known homolog of ACE, the

angiotensin-converting enzyme 2 (ACE2) has been identified in humans and rodents.1 ACE2 functions as a zinc metallopeptidase with carboxypeptidase activity. ACE2 hydrolyzes AngI to generate

Ang(1–9), a peptide with unknown effects on the vascular bed. In addition, it catalyzes hydrolysis of AngII to Ang (1–7), a potent vasodilator and antiproliferative peptide. The efficacy of

ACE2 for the conversion of AngI to Ang (1–9) in humans is ∼400-fold lower than for the generation of Ang (1–7) from AngII.2, 3 ACE2 may act as a negative regulator of ACE and the RAAS by

limiting the production or antagonizing the vasoconstrictive effect of AngII and facilitating the formation of Ang (1–7). It was initially hypothesized that disruption of the delicate

balance between ACE and ACE2 would result in abnormal blood pressure control.4 In that line of thinking, increased ACE2 activity might protect against increases in blood pressure and ACE2

deficiency might lead to hypertension. In early animal studies, a potential role of ACE2 for blood pressure regulation and the pathogenesis of hypertension was supported by the fact that

_ACE2_ maps to the X chromosome and shows colocalization with blood pressure quantitative trait loci (QTLs)5 that have been identified in polygenetic rat models of hypertension, including

the stroke-prone spontaneously hypertensive rat (SHRSP)6 and the salt-sensitive Sabra hypertensive (SBH/y) rat model of genetic hypertension.7 In addition, it was reported that renal ACE2

expression was decreased in these hypertensive strains when compared with the normotensive reference strains.5 Moreover, stimulation of RAAS gene expression in SHR by all-trans retinoic acid

(at-RA) for 3 weeks increased natively low kidney ACE2 mRNA, which was associated with a reduction in blood pressure. However, other data were at variance with a causal role for ACE2 in the

pathogenesis of hypertension. In the above study, ACE2 protein levels in SHR were increased and almost reached the levels of the control rats, with blood pressure elevated in comparison

with the controls, thus putting into question a straightforward association between renal ACE2 and blood pressure.8 In addition, in knockout mice lacking the _ACE2_ gene, blood pressure was

normal or only modestly increased in comparison with their background strain, despite increased AngII plasma and tissue levels.5, 9 These findings suggest that the role of ACE2 in blood

pressure control is not a uniform phenomenon and is apparently context dependent. In humans, data so far do not support a role for ACE2 in the genetics of hypertension, given the absence of

association between single-nucleotide polymorphisms in the _ACE2_ locus and essential hypertension.10 Thus, data on the role of ACE2 in blood pressure regulation and hypertension are still

inconclusive. To address a possible role for renal ACE2 in established hypertension, we analyzed kidney ACE2 mRNA, ACE2 protein and ACE2 enzyme activities in two different genetic rat models

of hypertension, namely the polygenetic SHRSP and the monogenetic TGR(mREN2)27 rat models in comparison with their normotensive reference strains, Wistar-Kyoto (WKY) and the Spraque-Dawley

(SD) rats, respectively. METHODS ANIMALS This study was conducted in accordance with the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. All animal

experiments were approved by the animal research ethics committee of the University Medical Centre Groningen. SHRSP, WKY, TGR(mREN2)27 and SD rats were obtained from our own colony in

Berlin. SHRSP and WKY strains are directly derived from the original colonies from Heidelberg that were used in the co-segregation analysis in which the first blood pressure QTL on rat

chromosome X was identified. Moreover, SHRSP and WKY animals with established hypertension were studied at a similar age of 14 weeks compared with the F2 hybrids derived from SHRSP and WKY

that were analyzed in the original linkage study.6 Homozygous TGR(mREN2)27 animals develop severe hypertension at an early age and were therefore studied at 8 weeks of age as reported.11

Rats were kept under conditions of regular 12 h diurnal cycles using an automated light switching device and climate-controlled conditions at a room temperature of 22 °C. The rats were fed a

normal pelleted diet containing 0.2% sodium chloride (NaCl) and had free access to food and water. Systolic blood pressure and urinary albumin excretion were determined as previously

reported.12 Animals were killed under Ketamin HCl (87 mg kg−1 body weight; Ketanest S, Pfizer, Karlsruhe, Germany) and Xylazine (13 mg kg−1 body weight; Rompun, Beyer, Leverkusen, Germany)

anesthesia at 14 weeks of age. After induction of anesthesia, the abdomen was opened by a vertical incision. Blood was drawn from the abdominal aorta and through the same puncture saline was

infused, allowing both kidneys to be perfused before excision. Using this procedure precludes contamination of renal tissue by blood or serum components and thus eliminates the possibility

of serum ACE2 tissue contamination. The absence of blood is visually verified by the absence of erythrocytes in the lumen of renal blood vessels in Figure 2. Both kidneys were excised, and

the left kidney was additionally dissected into cortex and medulla, and immediately frozen in liquid nitrogen and stored at −80 °C. REAL-TIME RT-PCR FOR ACE2 To quantify mRNA expression of

ACE2 in kidney, we used the real-time quantitative RT (‘TaqMan’) PCR. Appropriate primers and fluorogenic probes were designed with the PrimerExpress software (Applied Biosystems, Darmstadt,

Germany). The ABI PRISM 7000 SDS instrument in conjunction with the ABI TaqMan Universal Master Mix (Applied Biosystems) was used to perform the assays. The reaction volume was 25 μl with a

final concentration of 900 nM for the primers and 200 nM for the probes. PCR conditions were used as recommended by the manufacturer. The primers were obtained from Proligo (Paris, France)

with forward (F) and reverse (R) primer sequences F: 5′-GAGGAGAATGCCCAAAAGATGA-3′ and R: 5′-GAAATTTTGGGCGATCTTGGA-3′. The fluorogenic probe was synthesized by TIB Molbiol (Berlin, Germany)

(5′FAM-CTGCGGCCAAATGGTCTGCCTT-3′ TAMRA). Relative quantitation was performed using the standard curve method. For each gene, a PCR fragment containing the sequence of the TaqMan system was

generated. In all, seven serial 1:10 dilutions of this fragment served as a standard curve that was assayed together with the corresponding unknown samples on each plate. Every sample was

measured in triplicate. To normalize our expression data, we used porphobilinogen deaminase (PBGD) as a housekeeping gene.11 ACE2 IMMUNOHISTOCHEMISTRY Angiotensin-converting enzyme 2

immunohistochemistry was performed on frozen and paraffin kidney sections. Frozen slides were fixed in acetone for 10 min. Paraffin sections were incubated overnight at +80 °C in Tris-HCl

buffer (pH 9). A polyclonal rabbit anti-ACE2 antiserum (a kind gift of the ACE2 antibody from Millennium Pharmaceuticals Inc., Cambridge, MA, USA)13 diluted in phosphate-buffered saline

(PBS) and supplemented with 1% bovine serum albumin, in a concentration of 1:750 for frozen and 1:500 (WKY) or 1:750 (TGR(mREN2)27, SD and SHRSP) for paraffin sections was incubated for 1 h

at room temperature. Endogenous peroxidase was blocked for 30 min (0.075% hydrogen peroxide (H2O2) in PBS, pH 7.4) for paraffin sections before and for frozen sections after primary Ab

incubation. Antibody binding was detected using sequential incubations with peroxidase-labeled goat anti-rabbit and peroxidase-labeled rabbit anti-goat antibodies (GARPO/RAGPO Dako,

Glostrup, Denmark). Normal rat serum (1%) was added to the secondary antibodies to block a specific binding. Peroxidase activity was developed by using 3-amino-9-ethylcarbazole (AEC) for 10 

min containing 0.03% H2O2. Counterstaining was performed using Mayer's hematoxylin. In all, three types of control tests were performed to determine the specificity of the antibody.

First, control sections were incubated with anti-ACE2 antibody solutions, which were pre-incubated with the synthetic peptide to which the antibody was raised (peptide sequence:

NTNITEENVQNMNNAGDKW aa51–69, Pepscan Systems BV, Lelystad, The Netherlands). Second, sections were incubated with unrelated rabbit polyclonal antibodies (anti-alpha1Inhibitor3 or

anti-Nitrotyrosine) and third, the sections were incubated with PBS in the absence of the primary antibodies. These control sections did not reveal any staining. ANALYSIS OF STRUCTURAL

CHANGES The structures that were positive for ACE2 were analyzed and scored semiquantitatively in a blinded manner. The combined intensity and distribution of ACE2 immunostaining were

determined on a scale of 0 to 2+ (0 absent; +/− very weak staining; + moderate staining; ++ strong staining) for different parts of the glomerulus (mesangium, endothelium, visceral

epithelium and parietal epithelium), tubuli (proximal and distal tubuli, collecting ducts), vascular structures in the cortex (vascular smooth muscle cells, vascular endothelium, peritubular

capillaries) and vascular structures in the medulla (vasa recta). ACE2 ACTIVITY Angiotensin-converting enzyme 2 activity was measured according to the method by Vickers _et al._3 Renal

tissue was homogenized in assay buffer (50 mM 2morpholinoethanesulfonic acid, 300 mM NaCl, 10 μM zinc chloride (ZnCl2), 0.01% Brij-35, pH 6.5). Protein concentration was determined using

Roti-Quant (Carl Roth GmbH and Co. KG, Karlsruhe, Germany) according to the manufacturer's instruction. We used Mca-APK(Dnp) (Biosynthan GmbH, Berlin, Germany) that was dissolved in

dimethyl sulfoxide (DMSO; 50 μM, final concentration) as the ACE2 substrate. The assay was performed in assay buffer and was started by adding 10 μl of tissue homogenate. After 2 h of

incubation at ambient temperature (24 °C), the reaction was suppressed by adding 100 μM _o_-phenanthrolin (final concentration). Parallel control tests were performed in the presence of 1 μM

DX600 (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany) (data not shown).14 After centrifugation (10 min, 10 000 × _g_), the fluorescence was measured at 320 nm (excitation) and 405 nm

(emission) using the Perkin-Elmer fluorescence reader Lambda 5 (Perkin-Elmer LAS GmbH, Rodgau, Germany). The molecular standardization was performed using Mca-AP (Biosynthan GmbH) and

calculated per mg protein. The functionality of the assay was proven by a standardized solution with defined, recombinant ACE2 activity (R&D Systems GmbH). STATISTICS Data are presented

as mean±s.d. The differences between the hypertensive strain and its normotensive control were analyzed using the Mann–Whitney _U_-test (SPSS 12.0; SPSS Inc., Chicago, IL, USA). Significant

differences were obtained when _P_<0.05, and all _P_-values were calculated from two-tailed tests of statistical significance. RESULTS RAT CHARACTERISTICS Table 1 summarizes the

characteristics for the hypertensive and normotensive rat strains. Both SHRSP and TGR(mREN2)27 rats showed significantly higher blood pressure and lower body weights than their respective

controls. Homozygous TGR(mREN2)27 rats already showed a significant increase in urinary albumin excretion at 8 weeks of age whereas SHRSP showed normal albumin excretion levels that were

similar to the normotensive rat strains. ACE2 MRNA Angiotensin-converting enzyme 2 mRNA levels were measured using quantitative RT-PCR in renal cortex and medulla. The results are presented

in Figure 1. SHRSP rats had similar ACE2 mRNA levels compared with WKY in both cortex and medulla. ACE2 mRNA levels in TGR(mREN2)27 cortex were lower than in SD cortex, but this did not

reach statistical significance. No differences in ACE2 mRNA levels were found between TGR(mREN2)27 and SD medulla. ACE2 IMMUNOHISTOCHEMISTRY The immunohistochemical staining pattern of renal

ACE2 was uniform in all rat strains, whether normotensive or hypertensive. Moreover, the pattern of ACE2 staining was consistent between frozen and paraffin sections. In the glomeruli,

moderate ACE2 expression was observed in parietal epithelial cells and abundant ACE2 expression in visceral epithelial cells, whereas the glomerular mesangial and endothelial cells were

consistently negative for ACE2 (Figure 2 and Table 2). In vascular structures, ACE2 was abundantly expressed in vascular smooth muscle cells (VSMCs) and endothelial cells, with the exception

of the endothelium of peritubular capillaries (Table 2). Remarkably, VSMCs of larger cortical radial (interlobular) arteries have less ACE2 expression than VSMCs of smaller preglomerular

arterioles. This effect was most pronounced in SHRSP and WKY rats. Proximal tubuli did not reveal ACE2 expression whereas distal tubuli showed weak, predominantly intracellular ACE2

expression on the basal side of the cells. Collecting ducts were consistently negative for ACE2. The extent of ACE2 protein expression was scored semiquantitatively for all the renal

structures in cortex and medulla and the results are presented in Table 2. No differences in ACE2 expression were found between SHRSP and WKY rats and between TGR(mREN2)27 and SD rats

(Figure 2). TISSUE ACE2 ACTIVITY In accordance with the renal mRNA and protein expression data, no differences were found in tissue ACE2 activity between the hypertensive strains and their

normotensive reference strains (Table 3). Notably, ACE2 activity was higher in SD and REN2 rats when compared with WKY and SHRSP rat strains. DISCUSSION The major finding of our study is the

absence of any differences in kidney ACE2 mRNA, ACE2 protein and ACE2 activity between the adult SHRSP, a model of polygenetic hypertension and its normotensive reference strain, the WKY

rat. Similarly, in a completely different model of monogenetic, renin-dependent hypertension, equal levels of kidney ACE2 mRNA, ACE2 protein and ACE2 activity were found in adult

hypertensive homozygous TGR(mREN2)27 animals and their normotensive reference strain, a transgenic negative SD rat. The hypothesis that linked ACE2 with blood pressure regulation was

initially supported by a study that analyzed renal ACE2 in genetic adult hypertension in rat models.5 These findings would be theoretically in line with the hypothesis that in conditions

with decreased ACE2 activity, blood pressure rises due to a prevailing AngII vasoconstrictor effect. Recent studies have re-examined the role of renal ACE2 in blood pressure regulation with

varying conclusions.10, 15, 16 In experimental studies, first, in knockout mice lacking the ACE2 gene, blood pressure is either normal or only mildly increased compared with control

littermates.5, 9, 17 In rats, Pendergrass _et al._18 found that hypertensive male mRen2.Lewis rats had lower cortical ACE2 activity than normotensive Lewis rats, but no difference in ACE2

activity was present between female hypertensive and normotensive rats in the same study. Paradoxically, male mRen2.Lewis had a higher blood pressure than females despite significantly

higher renal ACE2 activity. Thus, the association between lower renal ACE2 levels and higher blood pressure that was observed in the early studies is apparently not a uniform phenomenon, and

seems to be context dependent, as shown by the effect of gender in the Pendergast study. Human renal biopsy data illustrate the complexity of the possible associations between renal ACE2

and blood pressure. Wakahara _et al._19 showed that renal ACE2 is expressed synergistically with ACE, supporting pathophysiological relevance of the combination of the two, rather than for

ACE2 alone. Moreover, they found that blood pressure was an independent confounding factor for renal ACE/ACE2 ratio, at expression as well as at protein level, in patients with hypertension

secondary due to diverse renal conditions. These data support the presence of an association between renal ACE/ACE2 balance and hypertension in renal patients, with a higher ACE/ACE2 ratio

being associated with hypertension. These association data in renal patients, however, do not allow to dissect between hypertension as a cause or consequence of elevated blood pressure, or

to conclude upon a role of ACE2 in essential hypertension, in the absence of renal disease. Epidemiological data so far have not provided support for a role of ACE2 in hypertension. Neither

in candidate gene studies10 nor in two recent genome-wide association studies20, 21 was the _ACE2_ locus associated with blood pressure or hypertension. The intrarenal localization of ACE2

could potentially provide clues as to its functional role. However, data on the intrarenal localization of ACE2 are not consistent. Our current findings in rat renal tissue are somewhat at

variance with earlier reports that provided varying results. In the current study we found predominant glomerular and endothelial ACE2 staining with weak staining in distal and negative

staining in proximal tubuli. Others, however, have reported ACE2-positive proximal tubuli and/or ACE2-negative glomeruli in male SD rats using commercially available goat polyclonal

anti-ACE2 antibodies22 and in female SD rats with self-prepared mouse monoclonal and rabbit polyclonal anti-ACE2 antibodies.23, 24 These reports strongly emphasize the lack of ACE2 protein

in glomeruli. On the other hand, with the above mentioned commercially available goat polyclonal anti-ACE2 antibody, ACE2-positive staining was subsequently reported to be present not only

in tubular segments, but also in glomeruli and endothelial cells of male adult SD rats.25 Similarly, in adult SHR and WKY rats, ACE2 mRNA and protein was present in proximal tubuli and large

vessels with weak distal tubular and glomerular presence using the initial rabbit polyclonal anti-ACE2.26 Considering these between-laboratory discrepancies, in the current study we took

great care to rigorously test validity and reproducibility of our immunohistochemistry data. To this purpose we tested different antibodies, and moreover, we reproduced the findings on

paraffin as well as frozen sections. The similarity of our findings on renal ACE2 in paraffin and frozen sections, as well as the reproducibility of it for two different hypertensive and

normotensive strains, supports the robustness of our findings. Hence, although our findings are internally consistent, for the moment between-laboratory differences are still difficult to

interpret and hamper a consistent overall conclusion on the intrarenal localization of ACE2. It should be noted that there are species differences in the renal localization of ACE2. ACE2

expression pattern in human kidneys is similar to the one in mouse kidneys,1, 22, 27 with primary localization in the proximal tubular epithelium. However, inconsistencies can be found in

mouse glomerular ACE2 presence as described even by the same group.28, 29 Besides, kinetic differences in AngI and AngII metabolism are shown to be exist between rat, human and sheep

kidneys.25, 30, 31 There are some limitations to our study. First, our data were obtained in adult animals with established hypertension and hence do not rule out a role for renal ACE2 in

the early onset of hypertension. Second, because of technical issues, we only can provide data on ACE2 whereas the relevant pathogenetic entity might well be ACE/ACE2 ratio. Taking these

limitations in mind, our data do not support a role for renal ACE2 in established hypertension in genetically determined hypertension in rats. Yet, our data do not completely rule out a

possible contribution to specific hypertensive conditions such as Sabra rat model, or an important (protective) role for tissue ACE2 at local organ-specific sites.28, 32, 33, 34, 35 In

conclusion, kidney ACE2 expression and activity is similar in polygenetic and monogenetic adult rat models of hypertension as compared with their normotensive reference strains. The precise

role of renal ACE2 in hypertension remains to be established. CONFLICT OF INTEREST The authors declare no conflict of interest. REFERENCES * Hamming I, Cooper ME, Haagmans BL, Hooper NM,

Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H . The emerging role of ACE2 in physiology and disease. _J Pathol_ 2007; 212: 1–11. Article  CAS  Google Scholar  * Tipnis

SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ . A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. _J

Biol Chem_ 2000; 275: 33238–33243. Article  CAS  Google Scholar  * Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M,

Nichols A, Tummino P . Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. _J Biol Chem_ 2002; 277: 14838–14843. Article  CAS  Google Scholar 

* Yagil Y, Yagil C . Hypothesis: ACE2 modulates blood pressure in the mammalian organism. _Hypertension_ 2003; 41: 871–873. Article  CAS  Google Scholar  * Crackower MA, Sarao R, Oudit GY,

Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM .

Angiotensin-converting enzyme 2 is an essential regulator of heart function. _Nature_ 2002; 417: 822–828. Article  CAS  Google Scholar  * Hilbert P, Lindpaintner K, Beckmann JS, Serikawa T,

Soubrier F, Dubay C, Cartwright P, De Gouyon B, Julier C, Takahasi S . Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats.

_Nature_ 1991; 353: 521–529. Article  CAS  Google Scholar  * Yagil C, Sapojnikov M, Kreutz R, Zurcher H, Ganten D, Yagil Y . Role of chromosome X in the Sabra rat model of salt-sensitive

hypertension. _Hypertension_ 1999; 33: 261–265. Article  CAS  Google Scholar  * Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K . Upregulation of angiotensin-converting enzyme 2 by

all-trans retinoic acid in spontaneously hypertensive rats. _Hypertension_ 2004; 44: 907–912. Article  CAS  Google Scholar  * Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N,

Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM . Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. _J Clin Invest_ 2006; 116:

2218–2225. Article  CAS  Google Scholar  * Benjafield AV, Wang WY, Morris BJ . No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. _Am J

Hypertens_ 2004; 17: 624–628. Article  CAS  Google Scholar  * Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R . Expression and response to angiotensin-converting

enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. _J Pharmacol Exp Ther_ 2006; 316: 8–16. Article

  CAS  Google Scholar  * Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M . Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron

number. _J Hypertens_ 2000; 18: 777–782. Article  CAS  Google Scholar  * Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R,

Breitbart RE, Acton S . A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. _Circ Res_ 2000; 87: E1–E9. Article  CAS  Google

Scholar  * Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, Parry T, Kent R, Enright J, Wu QL, Conley G, DeOliveira D, Morganelli L, Ducar M, Wescott CR, Ladner RC . Novel

peptide inhibitors of angiotensin-converting enzyme 2. _J Biol Chem_ 2003; 278: 15532–15540. Article  CAS  Google Scholar  * Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP,

Katovich MJ, Ferrario CM, Raizada MK . Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. _Exp Physiol_ 2005; 90:

783–790. Article  CAS  Google Scholar  * Riviere G, Michaud A, Breton C, VanCamp G, Laborie C, Enache M, Lesage J, Deloof S, Corvol P, Vieau D . Angiotensin-converting enzyme 2 (ACE2) and

ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. _Hypertension_ 2005; 46: 1169–1174. Article  CAS  Google Scholar  * Gurley SB,

Coffman TM . Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. _Exp Physiol_ 2008; 93: 538–542. Article  CAS  Google Scholar  * Pendergrass KD, Pirro NT,

Westwood BM, Ferrario CM, Brosnihan KB, Chappell MC . Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats. _Am J Physiol Heart

Circ Physiol_ 2008; 295: H10–H20. Article  CAS  Google Scholar  * Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I, Miyamori I . Synergistic expression of

angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. _Endocrinology_ 2007; 148: 2453–2457. Article  CAS 

Google Scholar  * Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Kottgen A, Vasan RS, Rivadeneira F,

Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O′Donnell CJ, Hofman A, Rotter JI, Coresh

J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van Duijn CM . Genome-wide association study of blood

pressure and hypertension. _Nat Genet_ 2009; 41: 677–687. Article  CAS  Google Scholar  * Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC,

Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F, Farrall M, Tanaka T, Wallace C, Chambers JC, Khaw KT, Nilsson P, van der Harst P, Polidoro S, Grobbee DE, Onland-Moret NC, Bots ML,

Wain LV, Elliott KS, Teumer A, Luan J, Lucas G, Kuusisto J, Burton PR, Hadley D, McArdle WL, Brown M, Dominiczak A, Newhouse SJ, Samani NJ, Webster J, Zeggini E, Beckmann JS, Bergmann S, Lim

N, Song K, Vollenweider P, Waeber G, Waterworth DM, Yuan X, Groop L, Orho-Melander M, Allione A, Di Gregorio A, Guarrera S, Panico S, Ricceri F, Romanazzi V, Sacerdote C, Vineis P, Barroso

I, Sandhu MS, Luben RN, Crawford GJ, Jousilahti P, Perola M, Boehnke M, Bonnycastle LL, Collins FS, Jackson AU, Mohlke KL, Stringham HM, Valle TT, Willer CJ, Bergman RN, Morken MA, Doring A,

Gieger C, Illig T, Meitinger T, Org E, Pfeufer A, Wichmann HE, Kathiresan S, Marrugat J, O′Donnell CJ, Schwartz SM, Siscovick DS, Subirana I, Freimer NB, Hartikainen AL, McCarthy MI,

O′Reilly PF, Peltonen L, Pouta A, de Jong PE, Snieder H, van Gilst WH, Clarke R, Goel A, Hamsten A, Peden JF, Seedorf U, Syvanen AC, Tognoni G, Lakatta EG, Sanna S, Scheet P, Schlessinger D,

Scuteri A, Dorr M, Ernst F, Felix SB, Homuth G, Lorbeer R, Reffelmann T, Rettig R, Volker U, Galan P, Gut IG, Hercberg S, Lathrop GM, Zelenika D, Deloukas P, Soranzo N, Williams FM, Zhai G,

Salomaa V, Laakso M, Elosua R, Forouhi NG, Volzke H, Uiterwaal CS, van der Schouw YT, Numans ME, Matullo G, Navis G, Berglund G, Bingham SA, Kooner JS, Connell JM, Bandinelli S, Ferrucci L,

Watkins H, Spector TD, Tuomilehto J, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham NJ, Uda M, Jarvelin MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR, Caulfield M, Munroe

PB . Genome-wide association study identifies eight loci associated with blood pressure. _Nat Genet_ 2009; 41: 666–676. Article  CAS  Google Scholar  * Gembardt F, Sterner-Kock A, Imboden H,

Spalteholz M, Reibitz F, Schultheiss HP, Siems WE, Walther T . Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. _Peptides_ 2005; 26: 1270–1277.

Article  CAS  Google Scholar  * Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, Penninger J, Ferrario CM . Enhanced renal immunocytochemical expression of ANG-(1-7) and

ACE2 during pregnancy. _Hypertension_ 2003; 42: 749–753. Article  CAS  Google Scholar  * Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, Ferrario CM, Davis WP,

Brosnihan KB . Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. _Am J Physiol Regul Integr Comp Physiol_

2007; 293: R169–R177. Article  CAS  Google Scholar  * Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD . The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by

rat proximal tubules. _Am J Physiol Renal Physiol_ 2005; 288: F353–F362. Article  CAS  Google Scholar  * Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, Smith AI, Thomas

MC . Developmental expression of ACE2 in the SHR kidney: a role in hypertension? _Kidney Int_ 2006; 70: 34–41. Article  CAS  Google Scholar  * Hamming I, Timens W, Bulthuis ML, Lely AT,

Navis GJ, van Goor H . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. _J Pathol_ 2004; 203: 631–637.

Article  CAS  Google Scholar  * Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D . Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective

combination? _Hypertension_ 2004; 43: 1120–1125. Article  CAS  Google Scholar  * Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D . Glomerular localization and expression of

angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. _J Am Soc Nephrol_ 2006; 17: 3067–3075. Article  CAS  Google Scholar  * Rice GI,

Thomas DA, Grant PJ, Turner AJ, Hooper NM . Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. _Biochem J_ 2004; 383:

45–51. Article  CAS  Google Scholar  * Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, Rose JC, Chappell MC . Angiotensin metabolism in renal proximal tubules, urine,

and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. _Am J Physiol Renal Physiol_ 2007; 292: F82–F91. Article  CAS  Google Scholar  * Lely AT, Hamming I, van Goor

H, Navis GJ . Renal ACE2 expression in human kidney disease. _J Pathol_ 2004; 204: 587–593. Article  CAS  Google Scholar  * Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V,

Burrell LM . Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. _Exp Physiol_ 2008; 93: 622–630. Article  CAS  Google Scholar

  * Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI . Myocardial infarction increases ACE2 expression in rat and

humans. _Eur Heart J_ 2005; 26: 369–375. Article  CAS  Google Scholar  * Goulter AB, Goddard MJ, Allen JC, Clark KL . ACE2 gene expression is up-regulated in the human failing heart. _BMC

Med_ 2004; 2: 19. Article  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Barry Jutten for technical assistance. This study was supported by University Medical Center

Groningen, Graduate School for Drug Exploration (GUIDE), and grants from the BMBF, Grant KGCV1, 01GS0416 in NGFN2 and the DFG Grant GRK 865 ‘Vaskuläre Regulationsmechanismen’. AUTHOR

INFORMATION Author notes * Jelena Kamilic and Inge Hamming: These authors contributed equally to this work. AUTHORS AND AFFILIATIONS * Department of Pathology and Medical Biology, University

Medical Center Groningen, University of Groningen, Groningen, The Netherlands Jelena Kamilic, Inge Hamming & Harry van Goor * Department of Clinical Pharmacology, Charité-University

Medicine Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany Reinhold Kreutz, Juliane Bolbrinker & Ibrahim Nassar * Biochemical Neurobiology, Leibniz-Institut für Molekulare

Pharmakologie (FMP), Berlin, Germany Wolf-Eberhard Siems * Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The

Netherlands Judith C Sluimer * Department of Cardiovascular Physiology, Hull York Medical School, The University of Hull, Hull, UK Thomas Walther * Department of Nephrology, University

Medical Center Groningen, University of Groningen, Groningen, The Netherlands Gerjan J Navis Authors * Jelena Kamilic View author publications You can also search for this author inPubMed 

Google Scholar * Inge Hamming View author publications You can also search for this author inPubMed Google Scholar * Reinhold Kreutz View author publications You can also search for this

author inPubMed Google Scholar * Juliane Bolbrinker View author publications You can also search for this author inPubMed Google Scholar * Wolf-Eberhard Siems View author publications You

can also search for this author inPubMed Google Scholar * Ibrahim Nassar View author publications You can also search for this author inPubMed Google Scholar * Judith C Sluimer View author

publications You can also search for this author inPubMed Google Scholar * Thomas Walther View author publications You can also search for this author inPubMed Google Scholar * Gerjan J

Navis View author publications You can also search for this author inPubMed Google Scholar * Harry van Goor View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to Jelena Kamilic. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kamilic, J., Hamming, I., Kreutz, R. _et

al._ Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. _Hypertens Res_ 33, 123–128 (2010). https://doi.org/10.1038/hr.2009.191

Download citation * Received: 03 June 2009 * Revised: 27 September 2009 * Accepted: 14 October 2009 * Published: 20 November 2009 * Issue Date: February 2010 * DOI:

https://doi.org/10.1038/hr.2009.191 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently

available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * ACE2 * kidney * rat * stroke-prone SHR